Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery

17 Jul 2018

Abstract excerpt

Lipid nanoparticles (LNPs) are formulated using unmodified cholesterol. However, cholesterol is naturally esterified and oxidized in vivo, and these cholesterol variants are differentially trafficked in vivo via lipoproteins including LDL and VLDL. We hypothesized that incorporating the same cholesterol variants into LNPs—which can be structurally similar to LDL and VLDL—would alter nanoparticle targeting in vivo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol and Lipid Metabolism
Share to MicroRNA in disease regulation
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30016076
DOI: 10.1021/acsnano.8b03640

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle DeliveryPMID 30016076Read ↗

The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid StructureSemantic proximity Read ↗

Lipid Nanoparticles for In Vivo Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical TargetsSemantic proximity Read ↗

Diverse lipid conjugates for functional extra-hepatic siRNA delivery <i>in vivo</i>Semantic proximity Read ↗

High-density lipoproteins for the systemic delivery of short interfering RNASemantic proximity Read ↗

Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1Semantic proximity Read ↗

Lipid-siRNA conjugate accesses a perivascular transport mechanism and achieves widespread and durable knockdown in the central nervous systemSemantic proximity Read ↗

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imagingSemantic proximity Read ↗

Targeted delivery of RNA-based therapeutics enables functional analysis of macrophage subpopulationsSemantic proximity Read ↗

Lipid nanoparticles incorporating a GalNAc ligand enable in vivo liver <i>ANGPTL3</i> editing in wild-type and somatic <i>LDLR</i> knockout non-human primatesSemantic proximity Read ↗

Intravenous lipid-siRNA conjugate mediates gene silencing at the blood-brain barrier and blood-CSF barrierSemantic proximity Read ↗

A Rapidly Excretable, ROS-Scavenging Ionizable Lipid Decouples mRNA Delivery Potency from ToxicitySemantic proximity Read ↗

High-throughput <i>in vivo</i> screening using barcoded mRNA identifies lipid nanoparticles with extrahepatic tropism for cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.